We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Patented Sample Preparation Kit to Streamline DNA and RNA Sequencing Studies

By LabMedica International staff writers
Posted on 31 May 2012
Biotech and genomic researchers can now work with a patented new kit that optimizes sample preparation for DNA or RNA analysis whether performed manually or on a next generation sequencing (NGS) platform.

Rubicon Genomics, Inc. More...
(Ann Arbor, MI, USA) a well-known developer and manufacturer of sample-specific preanalytical processes to improve the performance and capabilities of DNA and RNA analytical platforms for research and clinical testing, has released the first product in its new line of the ThruPLEX sample preparation kits.

The ThruPLEX-FD kit turns sample preparation into a streamlined one-tube, three-step process without intermediate purifications, transfers, columns, or gels. The reduced steps and material transfers decrease the likelihood of experimental variability, bias, and contamination. DNA is sequencing-ready in two hours with as little as 15 minutes of hands-on time. The kit’s reagents and protocols were specifically designed for use with samples as small as 50 picograms of human DNA and can be used in plasma, FFPE (formalin-fixed, paraffin-embedded) tissue sections, cDNA, and ChIP (chromatin immunoprecipitation) DNA applications. The results are superior repair, ligation, and amplification of the genomic DNA.

ThruPLEX-FD is currently available as 48-reaction, 12-index kits for sequencing on the Illumina Inc. (San Diego, CA, USA) HiSeq, MiSeq, and Genome Analyzer instruments. Similar kits are currently being developed for additional formats and platforms.

“The accelerated adoption of NGS technology has created a demand for faster and more sensitive sample preparation,” said Dr. James Koziarz, CEO of Rubicon. “Breaking with the traditional multistep process requiring intermediate transfers and purifications, ThruPLEX uses more efficient enzymology to repair, ligate, and amplify the DNA molecules in a single tube. Our patented three-step process enables high quality sequencing of clinical samples that were previously too small or degraded to be tested. ThruPLEX-FD highlights the power of this new technology, producing accurate and reproducible results from very small amounts of fragmented DNA. We believe our ThruPLEX products will facilitate wider use of NGS and look forward to releasing additional ThruPLEX products later this year.”

Related Links:

Rubicon Genomics, Inc.
Illumina Inc.



Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Alcohol Testing Device
Dräger Alcotest 7000
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.